Literature DB >> 26823860

Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.

Jie Ming1, Zeming Liu1, Wen Zeng2, Yusufu Maimaiti1, Yawen Guo1, Xiu Nie3, Chen Chen1, Xiangwang Zhao1, Lan Shi1, Chunping Liu1, Tao Huang1.   

Abstract

OBJECTIVE: To evaluate the significance of BRAF (V600E) and Ras mutations, and RET rearrangements in papillary thyroid cancer (PTC) in the South central region of China.
METHODS: We included patients from Union hospital's pathology archive diagnosed with PTC and meeting the criteria for BRAF mutation, RAS mutation, and RET rearrangement testing. Medical records were analyzed for BRAF and RAS mutation status, RET rearrangements (positive or negative), and a list of standardized clinicopathologic features.
RESULTS: Positive BRAF mutation was found to be significantly associated with age and extrathyroidal extension (P=0.011 and P=0.013, respectively). However, there was no significant association between BRAF mutation and sex, tumor size, histological subtype, multifocality, or accompanying nodular goiter and Hashimoto's. On the other hand, none of these characteristics of PTC were been found to be associated with RAS mutation. Additionally, the frequency of RET rearrangements was higher in patients ≤45 years old than that in patients >45 years old.
CONCLUSIONS: We demonstrated that the BRAF (V600E) mutation slightly correlated with the clinicopathological characteristics of PTC in the Han population. Furthermore, neither RAS mutation nor RET rearrangements were found to be associated with the clinicopathological characteristics of PTCs. Our work provides useful information on somatic mutations to predict the risk of PTC in different ethnic groups.

Entities:  

Keywords:  BRAF; Papillary thyroid cancer; RAS; RET

Mesh:

Substances:

Year:  2015        PMID: 26823860      PMCID: PMC4713646     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

1.  No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.

Authors:  Rue-Tsuan Liu; Yi-Ju Chen; Fong-Fu Chou; Chun-Liang Li; Wei-Li Wu; Po-Chin Tsai; Chao-Cheng Huang; Jiin-Tsuey Cheng
Journal:  Clin Endocrinol (Oxf)       Date:  2005-10       Impact factor: 3.478

2.  Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities.

Authors:  Sachin Gupta; Oluyomi Ajise; Linda Dultz; Beverly Wang; Daisuke Nonaka; Jennifer Ogilvie; Keith S Heller; Kepal N Patel
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2012-03

3.  BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.

Authors:  Dingxie Liu; Zhi Liu; Stephen Condouris; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2007-03-20       Impact factor: 5.958

4.  Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma.

Authors:  Zeming Liu; Xiaoyu Li; Lan Shi; Yusufu Maimaiti; Tianwen Chen; Zhi Li; Shuntao Wang; Yiquan Xiong; Hui Guo; Wenshan He; Chunping Liu; Xiu Nie; Wen Zeng; Tao Huang
Journal:  Int J Clin Exp Med       Date:  2014-08-15

5.  Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma.

Authors:  T J Musholt; P B Musholt; N Khaladj; D Schulz; G F Scheumann; J Klempnauer
Journal:  Surgery       Date:  2000-12       Impact factor: 3.982

6.  Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Authors:  Ian D Hay; Geoffrey B Thompson; Clive S Grant; Eric J Bergstralh; Catherine E Dvorak; Colum A Gorman; Megan S Maurer; Bryan McIver; Brian P Mullan; Ann L Oberg; Claudia C Powell; Jon A van Heerden; John R Goellner
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

7.  Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

Authors:  Gina M Howell; Sally E Carty; Michaele J Armstrong; Shane O Lebeau; Steven P Hodak; Christopher Coyne; Michael T Stang; Kelly L McCoy; Marina N Nikiforova; Yuri E Nikiforov; Linwah Yip
Journal:  Ann Surg Oncol       Date:  2011-05-19       Impact factor: 5.344

8.  The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.

Authors:  Michiko Fukahori; Akira Yoshida; Hiroyuki Hayashi; Mitsuyo Yoshihara; Shoichi Matsukuma; Yuji Sakuma; Shiro Koizume; Naoyuki Okamoto; Tetsuo Kondo; Munetake Masuda; Yohei Miyagi
Journal:  Thyroid       Date:  2012-05-31       Impact factor: 6.568

9.  Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.

Authors:  Jehad Abubaker; Zeenath Jehan; Prashant Bavi; Mehar Sultana; Sayer Al-Harbi; Muna Ibrahim; Abdulrahman Al-Nuaim; Mohammed Ahmed; Tarek Amin; Maha Al-Fehaily; Osama Al-Sanea; Fouad Al-Dayel; Shahab Uddin; Khawla S Al-Kuraya
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

10.  Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.

Authors:  Christopher Gouveia; Nhu Thuy Can; Alan Bostrom; James P Grenert; Annemieke van Zante; Lisa A Orloff
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-11       Impact factor: 6.223

View more
  11 in total

1.  Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.

Authors:  Chunping Liu; Tianwen Chen; Zeming Liu
Journal:  World J Surg Oncol       Date:  2016-09-06       Impact factor: 2.754

2.  Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis.

Authors:  Qin Zhang; Bo-Ji Liu; Wei-Wei Ren; Ya-Ping He; Xiao-Long Li; Chong-Ke Zhao; Yi-Feng Zhang; Wen-Wen Yue; Jia-Yi Zheng; Hui-Xiong Xu
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

3.  RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients.

Authors:  Yi-Huan Luo; Liang Liang; Rong-Quan He; Dong-Yue Wen; Guo-Fei Deng; Hong Yang; Yun He; Wei Ma; Xiao-Yong Cai; Jun-Qiang Chen; Gang Chen
Journal:  Oncotarget       Date:  2017-05-26

4.  BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.

Authors:  Najla Fakhruddin; Mark Jabbour; Michael Novy; Hani Tamim; Hisham Bahmad; Fadi Farhat; Ghazi Zaatari; Tarek Aridi; Gernot Kriegshauser; Christian Oberkanins; Rami Mahfouz
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

5.  The Long Non-Coding RNA RP5-1024C24.1 and Its Associated-Gene MPPED2 Are Down-Regulated in Human Thyroid Neoplasias and Act as Tumour Suppressors.

Authors:  Romina Sepe; Simona Pellecchia; Pierre Serra; Daniela D'Angelo; Antonella Federico; Maddalena Raia; Ricardo Cortez Cardoso Penha; Myriam Decaussin-Petrucci; Luigi Del Vecchio; Alfredo Fusco; Pierlorenzo Pallante
Journal:  Cancers (Basel)       Date:  2018-05-18       Impact factor: 6.639

6.  Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.

Authors:  Koorosh Semsar-Kazerooni; Grégoire B Morand; Alexandra E Payne; Sabrina D da Silva; Véronique-Isabelle Forest; Michael P Hier; Marc P Pusztaszeri; Michael Tamilia; Richard J Payne
Journal:  J Otolaryngol Head Neck Surg       Date:  2022-03-04

7.  Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.

Authors:  Chenlei Shi; Yong Guo; Yichen Lv; Abiyasi Nanding; Tiefeng Shi; Huadong Qin; Jianjun He
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

8.  Clinicopathological characteristics and prognosis of thyroid cancer in northwest China: A population-based retrospective study of 2490 patients.

Authors:  Meiling Huang; Changjiao Yan; Hongliang Wei; Yonggang Lv; Rui Ling
Journal:  Thorac Cancer       Date:  2018-09-12       Impact factor: 3.500

Review 9.  Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates.

Authors:  Natalia Pstrąg; Katarzyna Ziemnicka; Hans Bluyssen; Joanna Wesoły
Journal:  Mol Cancer       Date:  2018-08-08       Impact factor: 27.401

Review 10.  Herbal Active Ingredients: An Emerging Potential for the Prevention and Treatment of Papillary Thyroid Carcinoma.

Authors:  Yang Yang; Qin Chen; Wen-Ying Yu; Huan-Huan Zhang; Yu-Sen Zhong; Song-Zhao Zhang; Jia-Feng Wang; Chen-Huan Yu
Journal:  Biomed Res Int       Date:  2020-01-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.